Inflammation in patients with type 2 diabetes is independent of obesity, an observation that may partly explain the increased risk of cardiovascular disease among patients with diabetes.

A retrospective analysis of 69,418 patients with diabetes showed that elevated A1C levels were statistically significantly associated with higher risk of macrovascular events.

There was a great deal of hubbub when the FDA asked Amylin Pharmaceuticals to notify prescribers about the small incidence of pancreatitis associated with Byetta®(exenatide). As usual the lay press and many medical papers went for sensationalism and overreacted. My intern Harine Sampaio, Doctor of Pharmacy Candidate, University of Florida …

Gone is the insulin bong as Pfizer announces they have spent 2.8 billion on the marketing and development of the first inhaled insulin, but have received just 12 million in sales in 2007. This will be a great opportunity to educate those patients using Exubera.

Life can be sweeter if you cut out the sugar, say German researchers

Companies to Collaborate on the Development of Autoimmune Disease Treatments.

Merck & Co., announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for JANUVIA(TM) (sitagliptin), the only DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes.

Supplements of vitamin E may counteract complications in type-2 diabetics linked to an increased risk of heart disease.

Yet another diabetes drug has come under fire, after it was revealed last week that Byetta, manufactured and distributed by Eli Lilly and Amylin Pharmaceuticals, could be linked to acute pancreatitis in some patients.

Obesity increases the risk of developing diabetes, but nobody knows the details of why this is the case. Researchers at the Sahlgrenska Academy in Sweden have now identified a protein that may play a role in increasing the risk.